Table of Contents Author Guidelines Submit a Manuscript
Enzyme Research
Volume 2015, Article ID 321820, 4 pages
http://dx.doi.org/10.1155/2015/321820
Research Article

Determining the IC50 Values for Vorozole and Letrozole, on a Series of Human Liver Cytochrome P450s, to Help Determine the Binding Site of Vorozole in the Liver

Chemistry Department, Adelphi University, Garden City, NY 11530, USA

Received 3 July 2015; Accepted 26 October 2015

Academic Editor: Hartmut Kuhn

Copyright © 2015 Lendelle Raymond et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Bhatnagar, A. Häusler, K. Schieweck, M. Lang, and R. Bowman, “Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor,” Journal of Steroid Biochemistry and Molecular Biology, vol. 37, no. 6, pp. 1021–1027, 1990. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Wouters, R. De Coster, R. W. Tuman et al., “Aromatase inhibition by R 76713: experimental and clinical pharmacology,” Journal of Steroid Biochemistry, vol. 34, no. 1–6, pp. 427–430, 1989. View at Publisher · View at Google Scholar · View at Scopus
  3. R. De Coster, R. F. Van Ginckel, M. J. Callens, N. K. Goeminne, and B. L. Janssens, “Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors,” Cancer Research, vol. 52, no. 5, pp. 1240–1244, 1992. View at Google Scholar
  4. S. Jeong, M. M. Woo, D. A. Flockhart, and Z. Desta, “Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 5, pp. 867–875, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. P. M. Wood, L. W. L. Woo, M. P. Thomas, M. F. Mahon, A. Purohit, and B. V. L. Potter, “Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates,” ChemMedChem, vol. 6, no. 8, pp. 1423–1438, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. P. E. Goss, “Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor,” Breast Cancer Research and Treatment, vol. 49, no. 1, pp. S59–S65, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Hamilton and M. Piccart, “The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer,” Annals of Oncology, vol. 10, no. 4, pp. 377–384, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Biegon, S. W. Kim, D. L. Alexoff et al., “Unique distribution of aromatase in the human brain: in vivo studies with PET and [N-methyl-11C]vorozole,” Synapse, vol. 64, no. 11, pp. 801–807, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Biegon, N. Alia-Klein, and J. S. Fowler, “Potential contribution of aromatase inhibition to the effects of nicotine and related compounds on the brain,” Frontiers in Pharmacology, vol. 3, article 185, Article ID Article 185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Ozawa, K. Takahashi, K.-H. Akazawa et al., “PET of aromatase in gastric parietal cells using 11C-vorozole,” Journal of Nuclear Medicine, vol. 52, no. 12, pp. 1964–1969, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Biegon, S.-W. Kim, J. Logan, J. M. Hooker, L. Muench, and J. S. Fowler, “Nicotine blocks brain estrogen synthase (aromatase): in vivo positron emission tomography studies in female baboons,” Biological Psychiatry, vol. 67, no. 8, pp. 774–777, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Takahashi, K. Onoe, H. Doi et al., “Increase in hypothalamic aromatase in macaque monkeys treated with anabolic-androgenic steroids: PET study with [11C]vorozole,” Neuroreport, vol. 22, no. 7, pp. 326–330, 2011. View at Publisher · View at Google Scholar
  13. K. Takahashi, G. Yamagishi, T. Hiramatsu et al., “Practical synthesis of precursor of [N-methyl- 11C]vorozole, an efficient PET tracer targeting aromatase in the brain,” Bioorganic and Medicinal Chemistry, vol. 19, no. 4, pp. 1464–1470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Lidström, T. A. Bonasera, D. Kirilovas et al., “Synthesis, in vivo rhesus monkey biodistribution and in vitro evaluation of a 11C-labelled potent aromatase inhibitor: [N-methyl-11C]vorozole,” Nuclear Medicine and Biology, vol. 25, no. 5, pp. 497–501, 1998. View at Publisher · View at Google Scholar
  15. D. Kirilovas, M. Bergström, T. A. Bonasera et al., “In vitro evaluation of aromatase enzyme in granulosa cells using a [11C]vorozole binding assay,” Steroids, vol. 64, no. 4, pp. 266–272, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Takahashi, M. Bergström, P. Frändberg, E.-L. Vesström, Y. Watanabe, and B. Långström, “Imaging of aromatase distribution in rat and rhesus monkey brains with [11C]vorozole,” Nuclear Medicine and Biology, vol. 33, no. 5, pp. 599–605, 2006. View at Publisher · View at Google Scholar
  17. S. W. Kim, A. Biegon, Z. E. Katsamanis et al., “Reinvestigation of the synthesis and evaluation of [N-methyl-11C]vorozole, a radiotracer targeting cytochrome P450 aromatase,” Nuclear Medicine and Biology, vol. 36, no. 3, pp. 323–334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Biegon, D. L. Alexoff, S. W. Kim et al., “Aromatase imaging with [N-methyl-11C]vorozole PET in healthy men and women,” Journal of Nuclear Medicine, vol. 56, no. 4, pp. 580–585, 2015. View at Publisher · View at Google Scholar
  19. S. W. Kim, A. Biegon, J. M. Hooker et al., “Saturable, non-aromatase binding of [11C]vorozole in baboon liver,” Journal of Nuclear Medicine, vol. 52, article 415, 416 pages, 2011. View at Google Scholar
  20. S. C. Khojasteh, S. Prabhu, J. R. Kenny, J. S. Halladay, and A. Y. H. Lu, “Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 36, no. 1, pp. 1–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Tang, M. Chiba, J. Nishime et al., “Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome P450s,” Drug Metabolism and Disposition, vol. 28, no. 6, pp. 680–686, 2000. View at Google Scholar · View at Scopus
  22. A. Ghosal, N. Hapangama, Y. Yuan et al., “Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes,” Biopharmaceutics and Drug Disposition, vol. 24, no. 9, pp. 375–384, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. C. L. Crespi, V. P. Miller, and B. W. Penman, “Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450,” Analytical Biochemistry, vol. 248, no. 1, pp. 188–190, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. Y.-C. Kao, K. R. Korzekwa, C. A. Laughton, and S. Chen, “Evaluation of the mechanism of aromatase cytochrome p450,” European Journal of Biochemistry, vol. 268, no. 2, pp. 243–251, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Vanden Bossche, G. Willemsens, I. Roels et al., “R 76713, A new specific non-steriodal aromatase inhibitor,” Biochemical Pharmacology, vol. 40, pp. 1707–1718, 1990. View at Google Scholar
  26. M. D. W. G. Krekels, W. Wouters, and R. De Coster, “Aromatase inhibition by R 76 713: a kinetic analysis in rat ovarian homogenates,” Steroids, vol. 55, no. 2, pp. 69–73, 1990. View at Publisher · View at Google Scholar · View at Scopus
  27. M. D. W. G. Krekels, W. Wouters, R. De Coster, R. Van Ginckel, A. Leonaers, and P. A. J. Janssen, “Aromatase in the human choriocarcinoma JEG-3: inhibition by R 76 713 in cultured cells and in tumors grown in nude mice,” Journal of Steroid Biochemistry and Molecular Biology, vol. 38, no. 4, pp. 415–422, 1991. View at Publisher · View at Google Scholar · View at Scopus
  28. H. V. Bossche, G. Willemsens, I. Roels et al., “R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis,” Biochemical Pharmacology, vol. 40, no. 8, pp. 1707–1718, 1990. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Wouters, R. De Coster, D. Beerens et al., “Potency and selectivity of the aromatase inhibitor R 76,713. A study in human ovarian, adipose stromal, testicular and adrenal cells,” Journal of Steroid Biochemistry, vol. 36, no. 1-2, pp. 57–65, 1990. View at Publisher · View at Google Scholar · View at Scopus
  30. Q. Lu, Y. Liu, B. J. Long, D. Grigoryev, M. Gimbel, and A. Brodic, “The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer,” Breast Cancer Research and Treatment, vol. 57, no. 2, pp. 183–192, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. A. T. Drahushuk, B. P. McGarrigle, K. E. Larsen, J. J. Stegeman, and J. R. Olson, “Detection of CYP1A1 protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture,” Carcinogenesis, vol. 19, no. 8, pp. 1361–1368, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. W. M. A. Westerink, J. C. R. Stevenson, and W. G. E. J. Schoonen, “Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition,” Archives of Toxicology, vol. 82, no. 12, pp. 909–921, 2008. View at Publisher · View at Google Scholar
  33. M. Rahman, S. F. Lax, C. H. Sutter et al., “CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma,” Drug Metabolism and Disposition, vol. 36, no. 5, pp. 963–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. V. A. Eagling, J. F. Tjia, and D. J. Back, “Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes,” British Journal of Clinical Pharmacology, vol. 45, no. 2, pp. 107–114, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. M. F. Paine, P. Schmiedlin-Ren, and P. B. Watkins, “Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole,” Drug Metabolism and Disposition, vol. 27, no. 3, pp. 360–364, 1999. View at Google Scholar · View at Scopus